The selective effect of NSC-631570 on women reproductive cancers

First indications on the selective effect of NSC-631570 on the cancer cells were provided in an early study when different oxygen consumption by normal liver cells and Ehrlich's tumor ascetic cells after the incubation with NSC-631570 was revealed. In the tests on the Jurkat lymphoma model, NSC-631570 has been proven to be a strong apoptosis inductor. Profound research showed NSC-631570 brought about the depolarization of mitochondrial membranes and consequently the activation of caspases. NSC-631570 induced apoptosis in a panel of cancer cell lines (ovarian and cervical cancer HeLa, HeKB, HeKS32, HeBcl3, HeNFR and HeIKK, human colon cancer SW480, human renal carcinoma HEK293, human osteosarcoma MG-63) by activating the caspases of the intrinsic cell death pathway. Interestingly, non-transformed fibroblasts (hTERT) cell line was insensitive to the drug. In the tests on human ovarian and cervix carcinoma cells HeLa, squamous carcinoma cells WHCO5, normal kidney cell line Graham 293, and transformed kidney cell line Vero from African green monkey, NSC-631570 inhibited the tubulin polymerization and caused a metaphase block in cancer cells which is characterized by abnormal chromosomal distribution, and results in the formation of micronuclei and in apoptosis.

Biography

Wassil Nowicky is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute, Vienna, Austria. He has completed his Graduation to Diplom-Ingenieur at the Radio technical Faculty of the Technical University of Lviv, Ukraine. He is the inventor of the anticancer preparation on the basis of celandine alkaloids “NSC-631570”. He is the author of over 300 scientific articles dedicated to cancer research. He is a real member of the New York Academy of Sciences, member of the European Union for Applied Immunology and of the American Association for Scientific Progress, Honorary Doctor of the Yanka Kupala University in Hrodno, and Doctor "honoris causa" of the Open International University on Complex Medicine in Colombo.

Wassil Nowicky1, 2
1Nowicky Pharma, Austria
2Ukrainian Anti-Cancer Institute, Austria